Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Afficher d'autres versions (1)

New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized health...

Description complète

Détails bibliographiques
Auteurs principaux:	Ota, M, Odutola, A, Owiafe, P, Donkor, S, Owolabi, O, Brittain, N, Williams, N, Rowland-Jones, S, Hill, A, Adegbola, R, McShane, H
Format:	Journal article
Langue:	English
Publié:	2011

Documents similaires

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
par: Ota, M, et autres
Publié: (2011)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
par: Odutola, A, et autres
Publié: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
par: Odutola, A, et autres
Publié: (2012)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
par: Brookes, R, et autres
Publié: (2008)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
par: Roger H Brookes, et autres
Publié: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
par: Roger H. Brookes, et autres
Publié: (2011-01-01)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
par: Rowland, R, et autres
Publié: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
par: Pathan, A, et autres
Publié: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
par: Pathan, A, et autres
Publié: (2012)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
par: Meyer, J, et autres
Publié: (2013)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
par: Whelan, K, et autres
Publié: (2009)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
par: Owiafe, P, et autres
Publié: (2012)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
par: Ibanga, H, et autres
Publié: (2006)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
par: Meyer, J, et autres
Publié: (2013)

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
par: Imoukhuede, E, et autres
Publié: (2006)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
par: White, A, et autres
Publié: (2013)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
par: Harris, S, et autres
Publié: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
par: Sander, C, et autres
Publié: (2009)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
par: Kathryn T. Whelan, et autres
Publié: (2011-01-01)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
par: Mensah, V, et autres
Publié: (2017)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
par: Mcshane, H
Publié: (2008)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
par: Dieye, T, et autres
Publié: (2013)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
par: Hawkridge, T, et autres
Publié: (2008)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
par: Satti, I, et autres
Publié: (2014)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Publié: (2011-01-01)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
par: Rowland, R, et autres
Publié: (2013)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
par: Mcshane, H, et autres
Publié: (2016)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
par: Minassian, A, et autres
Publié: (2011)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
par: Scriba, T, et autres
Publié: (2011)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
par: Wajja, A, et autres
Publié: (2017)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
par: Anne Wajja, et autres
Publié: (2017-05-01)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
par: Tandakha N Dieye, et autres
Publié: (2013-01-01)

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
par: Mullarkey, C, et autres
Publié: (2013)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
par: Thomas, Z, et autres
Publié: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
par: Tandakha N. Dieye, et autres
Publié: (2013-01-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
par: Satti, I, et autres
Publié: (2014)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
par: Mcshane, H, et autres
Publié: (2005)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
par: Minhinnick, A, et autres
Publié: (2016)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
par: Tameris, M, et autres
Publié: (2014)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
par: Griffiths, K, et autres
Publié: (2011)